Diabetes Self-Management Blog

On March 11, drug manufacturer GlaxoSmithKline and biotechnology firm Tolerx announced that their investigational diabetes drug otelixizumab had failed to preserve beta-cell function in people with Type 1 diabetes in a late-stage clinical trial known as DEFEND-1. An estimated 800,000 people in the United States have Type 1 diabetes.

In people with Type 1, an autoimmune disorder in which the immune system attacks and destroys the insulin-producing beta cells, the pancreas produces little or no insulin. Otelixizumab, a type of drug known as a humanized anti-CD3 monoclonal antibody, works by targeting the receptors of certain immune system cells known as T lymphocytes. It was hoped that the drug’s action on the immune system could preserve the function of the beta cells, as measured by the level of C-peptide (a protein that shows how much insulin the body is producing) in the blood.

DEFEND-1 was a phase III clinical trial that enrolled 272 people ages 12 to 45 with new-onset Type 1 diabetes. (A phase III trial is a type of study in which a drug or treatment is given to large groups of people to determine its effectiveness, compare it to other treatments, and find out whether there are any side effects.) The trial was intended to determine whether a single, eight-day intravenous course of otelixizumab administered no more than 90 days after a person was first diagnosed with Type 1 diabetes could preserve the function of their beta cells. Results after 12 months showed that there had not been a change in the participants’ C-peptide levels.

According to Douglas J. Ringler, VMD, President and Chief Executive Officer of Tolerx, “While we are disappointed in the DEFEND-1 results of otelixizumab, we remain committed to the development and commercialization of the candidates in our pipeline, each of which has a distinct mechanism and target for correcting abnormal immune responses.” Jackie Parkin, Medicines Development Leader of GlaxoSmithKline, added that “Clearly these are disappointing data, but we are committed to working with Tolerx to better understand the results of this study and determine the way forward.”

New recruitment and dosing in a similar study has been suspended pending review of the DEFEND-1 results. Otelixizumab is currently in early clinical trials for other autoimmune conditions, including rheumatoid arthritis and thyroid eye disease.

To learn more, read the piece “GSK drug fails in Type 1 study” or see the joint press release from GlaxoSmithKline and Tolerx.


  1. Diane where are you getting your numbers from? Far as I know an estimated 3 million people in the US have type 1 diabetes.

    Posted by riva |

Post a Comment

Note: All comments are moderated and there may be a delay in the publication of your comment. Please be on-topic and appropriate. Do not disclose personal information. Be respectful of other posters. Only post information that is correct and true to your knowledge. When referencing information that is not based on personal experience, please provide links to your sources. All commenters are considered to be nonmedical professionals unless explicitly stated otherwise. Promotion of your own or someone else's business or competing site is not allowed: Sharing links to sites that are relevant to the topic at hand is permitted, but advertising is not. Once submitted, comments cannot be modified or deleted by their authors. Comments that don't follow the guidelines above may be deleted without warning. Such actions are at the sole discretion of DiabetesSelfManagement.com. Comments are moderated Monday through Friday by the editors of DiabetesSelfManagement.com. The moderators are employees of R.A. Rapaport Publishing, Inc., and do not report any conflicts of interest. A privacy policy setting forth our policies regarding the collection, use, and disclosure of certain information relating to you and your use of this Web site can be found here. For more information, please read our Terms and Conditions.

Type 1 Diabetes
Researcher Seeks Type 1 Diagnosis Experiences (04/14/14)
What's Your Diabetes "Type"? Gestational, MODY, and Steroid-Induced (04/15/14)
"Get Diabetes Right" Initiative (04/07/14)
Study to Evaluate Needle-Free Glucagon Treatment (04/09/14)

Diabetes Research
Overweight People With Type 2 May Benefit From Gastric Banding (04/11/14)
Good News About Good Diabetes Self-Management (03/28/14)
Diabetes Developed at Midlife May Affect Brain Function in Old Age (03/21/14)
Many Americans Taking Meds That Work Against Each Other (03/14/14)

Diabetes News
FDA Approves Weekly Type 2 Diabetes Medicine (04/18/14)
Overweight People With Type 2 May Benefit From Gastric Banding (04/11/14)
FDA Panel Votes in Favor of Inhalable Insulin; Diet Drug Recalled (04/09/14)
Good News About Good Diabetes Self-Management (03/28/14)

Diane Fennell
FDA Approves Weekly Type 2 Diabetes Medicine (04/18/14)
Overweight People With Type 2 May Benefit From Gastric Banding (04/11/14)
FDA Panel Votes in Favor of Inhalable Insulin; Diet Drug Recalled (04/09/14)
Good News About Good Diabetes Self-Management (03/28/14)



Disclaimer of Medical Advice: You understand that the blog posts and comments to such blog posts (whether posted by us, our agents or bloggers, or by users) do not constitute medical advice or recommendation of any kind, and you should not rely on any information contained in such posts or comments to replace consultations with your qualified health care professionals to meet your individual needs. The opinions and other information contained in the blog posts and comments do not reflect the opinions or positions of the Site Proprietor.

Carbohydrate Restriction: An Option for Diabetes Management
Some people find that decreasing the amount of carbohydrate they eat can help with blood glucose control. Here’s what to know about this approach.

Insulin Patch Pumps: A New Tool for Type 2
Patch pumps are simpler to operate than traditional insulin pumps and may be a good option for some people with Type 2 diabetes who need insulin.

How Much Do You Know About Vitamins?
Learn what these micronutrients can and can’t do for you.

Complete table of contents
Subscription questions